Results: Accumulation of 89 Zr-anti-γH2AX-TAT in the tumours of mice that received chemotherapy was higher compared with vehicle-treated mice and was shown to be specifically mediated by γH2AX. In contrast, 18 F-FDG did not provide useful indications of therapeutic response.
Statement of Translational Relevance
Current chemotherapy regimens for pancreatic ductal adenocarcinoma do not appreciably prolong patient survival due to intrinsic or rapidly acquired resistance. To improve survival outcomes it is therefore critical to determine whether a patient is responding to treatment as early as possible so that a futile treatment can be quickly replaced with one which is more effective. Monitoring response to therapy by PET is attractive as this imaging technique can detect the early molecular indications of treatment efficacy. The standard clinical PET imaging agent is 18 F-FDG which despite its widespread use has several limitations, including a tendency to accumulate non-specifically in areas of inflammation and an inability to differentiate focal mass-forming pancreatitis from pancreatic cancer.
As most chemotherapy agents are designed to cause DNA damage, we propose that monitoring the DNA damage response with the PET imaging agent 89 Zr-anti-γH2AX-TAT would provide a more direct measure of treatment efficacy.
INTRODUCTION
At present, less than 5% of patients diagnosed with pancreatic cancer will survive longer than 5 years.
(1) This poor prognosis is due in part to a lack of screening measures which result in most patients being diagnosed when the disease is in an advanced, metastatic state. Consequently, the opportunity for potentially curative surgical resection has usually been missed and the patient is typically offered chemo-and/or radiotherapy, or palliative treatments.(2) Standard chemotherapy regimens for advanced pancreatic cancer include gemcitabine, fluorouracil (5-FU), capecitabine, Nabpaclitaxel (Abraxane) and FOLFIRNOX. Response to single agent chemotherapy is typically less than 10%, and response to multi-agent chemotherapy (gemcitabine/nab-Paclitaxel and FOLFIRNOX) in the region of 25-30%. (3) (4) (5) The limited efficacy of these treatments with regard to prolonging patient survival is largely due to intrinsic or acquired resistance to these agents.(6,7) The ability, therefore, to monitor the efficacy of a particular chemotherapy early on during treatment would be advantageous as a futile treatment could be rapidly switched to an alternative therapy. hexokinase. However, unlike glucose-6-phosphate, the newly formed 18 F-FDG-6-phosphate is resistant to subsequent enzymatic metabolism and is retained within the cell, resulting in specific accumulation of the imaging agent within tumours. In addition to its roles in cancer detection and staging, 18 F-FDG has also been used successfully for monitoring response to various forms of therapy in many cancer types (17) (18) (19) (20) (21) (22) (23) (24) (25) , including pancreatic ductal adenocarcinoma (PDAC). (26) (27) (28) While the use of 18 
METHODS AND MATERIALS

General Methods
All reagents were purchased from Sigma-Aldrich unless otherwise stated and were used without further purification. The chelating agent p-SCN-Bn-DFO was purchased from Macrocyclics Inc.
(Dallas, TX). Water was deionised using a Barnstead NANOpure purification system (Thermo Scientific) and had a resistance of >18.2 MΩ cm −1 at 25 °C. Protein concentration measurements were made on a ND-1000 spectrophotometer (NanoDrop Technologies, Inc.). Instant thin-layer chromatography (iTLC) was performed on glass microfiber chromatography paper (Agilent Technologies) and strips were analysed with either a Bioscan AR-2000 radio-TLC scanner (Eckert & Ziegler) or a Cyclone Plus Phosphor Imager (PerkinElmer). pH was determined using pH indicator paper (Merck Millipore). Radioactivity measurements were made using a CRC®-25R dose calibrator (Capintec, Inc.).
Cell culture
KPC cells (B8484) were derived from Kras LSL-G12D/+ ; Trp53 LSL-R172H/+ ; Pdx1-Cre (KPC) tumours. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin, and 0.1 mg mL -1 streptomycin.
Cells were grown in a 37°C environment containing 5% CO2 and were harvested and passaged as required using Trypsin-EDTA solution. The cumulative length of culture was less than 6 months following retrieval from liquid nitrogen storage.
Preparation of 89 Zr-anti-γH2AX-TAT
Anti-γH2AX (DR1017, Merck Millipore) was modified with the cell-penetrating peptide TAT (GRKKRRQRRRPPQGYG) by a previously described method. Zirconium-89 in 1 M oxalic acid (sourced from VU Amsterdam) was adjusted to pH 7 by the addition of 1 M sodium carbonate. The resulting solution was added to a 2 mg mL −1 solution of the DFO-modified antibody to achieve a ratio of 0.1 MBq to 1 µg. The reaction mixture was incubated at room temperature for 1 h and the radiolabeling efficiency was determined by iTLC using an eluent of 50 mM ethylenediaminetetraacetic acid (EDTA) buffer (pH 6). The crude reaction mixture was purified by Sephadex-G50 size exclusion chromatography, eluting with 100 μL fractions of phosphate buffered saline (PBS; pH 7.4).
89 Zr-labelled TAT-modified rabbit IgG (RIgG-TAT) was used as a negative control, and synthesised from rabbit IgG as described above for 89 Zr-anti-γH2AX-TAT.
In vivo studies 
Ex vivo biodistribution experiments
Mice were euthanized by cervical dislocation and selected organs, tissues and blood were removed.
The samples were immediately rinsed with water, dried, and transferred into a pre-weighed counting tube. After weighing the filled counting tubes, the amount of radioactivity in each was measured using a 2480 WIZARD 2 or 1470 WIZARD gamma counter (PerkinElmer). Counts per minute were converted into radioactivity units (MBq) using calibration curves generated from known standards.
These values were decay-corrected to the time of injection, and the percentage of the injected dose per gram (%ID/g) of each sample was calculated.
Immunohistochemical staining for GLUT-1 and γH2AX
Sections of tumour allograft tissue were obtained at 7 µm thickness using a cryostat (OTF5000, Bright Instruments). Tissue sections were fixed in 4% paraformaldehyde for 10 minutes at room temperature, washed twice in PBS, then permeabilized in 1% triton/PBS for 10 minutes at room temperature. After 
Statistical Analyses
All statistical analyses and nonlinear regression were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). Data were tested for normality and analysed either by the unpaired, two-tailed Student's t-test where appropriate, or 1-way analysis of variance (ANOVA) for multiple comparisons, with TukeyDunnet's post-tests to calculate significance of differences between groups.
All data were obtained at least in triplicate and results reported as mean ± standard deviation, unless stated otherwise.
RESULTS
Zirconium-89 radiolabelling of DFO-anti-γH2AX-TAT
89 Zr-anti-γH2AX-TAT and 89 Zr-RIgG-TAT were routinely synthesized in high radiochemical yields (87.7±13.5% and 85.2±14.5%, respectively) and obtained in excellent purity (>99%) following G50
size-exclusion chromatography. See Fig. S1 for representative iTLC chromatograms.
Tumour uptake and radiotracer distribution
5-FU therapy
PET/CT images acquired three days after a single dose of 5-FU revealed higher uptake of 89 Zr-anti-γH2AX-TAT in tumours of treated mice compared with experimental controls (Fig. 1A) . Within this timeframe, the growth rate of KPC allografts in mice treated with a single dose of 5-FU was not significantly impeded compared with vehicle-treated mice (Fig. 1B) Zr-anti-γH2AX-TAT in the tumours of treated mice reached a value of 8.5±1.1 %ID/g (Table S1 ) which was higher than the vehicletreated mice and mice administered an imaging agent lacking γH2AX specificity, 89 Zr-RIgG-TAT (P<0.01; Table S1 ). These observations correlate well with immunohistochemical analysis of the harvested tumour allograft tissues ( Fig. 1D and Fig 1E) as significantly higher expression levels of γH2AX were measured in the tumours of 5-FU treated mice compared with tumours of vehicletreated mice (67±19 and 49±21 a.u., respectively; P<0.05).
Similar PET/CT imaging experiments with 18 F-FDG did not reveal any differences in tumour uptake after initiation of 5-FU treatment either at an early stage (Day 3) before any effect upon RTV was observed, or on Day 9 when the mean RTV of treated mice was significantly smaller than vehicle-treated mice ( Fig. 2A-C) . Ex vivo biodistribution analysis performed immediately after the final imaging session on Day 9 (Table S2 ) and immunohistochemical staining of harvested tumours confirmed these results and showed no significant difference in GLUT-1 expression levels ( Fig. 2D and 2E).
Gemcitabine therapy
PET/CT images acquired 3 days after a single administration of gemcitabine revealed higher uptake of 89 Zr-anti-γH2AX-TAT in the tumours of gemcitabine-treated mice compared with the non-specific controls (Fig. 3A) . Within this timeframe there was no significant difference in mean RTV compared with a vehicle-treated control cohort of mice (Fig 3B) . Analysis of the ex vivo biodistribution data (Table S3 ) indicated that uptake of 89 Zr-anti-γH2AX-TAT in the tumours of gemcitabine-treated mice reached a value of 6.8±0.6 %ID/g and was significantly higher than experimental controls ( Fig. 3C; P<0.01, Table S3 ). Confocal microscopy images obtained from tumour tissue sections revealed higher γH2AX expression levels in the tumours of gemcitabine-treated mice compared with tumours harvested from vehicle-treated mice (67±30 and 40±13 a.u., respectively; P<0.05) (Figs. 3D and 3E ).
In a similar fashion to the 5-FU therapy experiments, PET images acquired with 18 F-FDG did not reveal any significant difference in tumour uptake between gemcitabine-and vehicle-treated mice at Day 3 (before any effect on RTV was observed) or Day 8 when a significant difference in RTV between these groups could be measured (Fig. 4A-C) . Interestingly, analysis of the ex vivo biodistribution data acquired immediately after the final imaging session on Day 8 (Table S4) revealed significantly higher uptake of 18 anti-γH2AX-TAT is non-specific and is consistent with uptake levels expected from the enhanced permeability and retention (EPR) effect (48, 49) . This phenomenon is caused by the leaky vasculature within tumours which causes high molecular weight species such as 89 Zr-anti-γH2AX-TAT to passively extravasate to tumour tissue. In order to overcome this limitation, future investigations will be focused on amplifying the proportion of γH2AX-mediated signal by, for example, utilisation of lower molecular weight targeting vectors (to diminish the EPR effect(50)), pretargeting strategies (to improve T/B contrast ratios(51)), and molecularly-targeted CPPs (to improve tumour targeting(52)). 
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CONCLUSIONS
